Skip to main content
Premium Trial:

Request an Annual Quote

Eldan to Distribute MDI's MRSA Test in Israel, Palestinian Territories

Premium

Molecular Detection said today that life sciences and diagnostics distributor Eldan, part of the Neopharm Group, will exclusively distribute MDI's Detect-Ready MRSA Panel in Israel and the Palestinian territories.

Detect-Ready MRSA is a qualitative real-time PCR in vitro diagnostic test marketed in the European Union and Australia and in late-stage development in the US.

The test is CE-Marked for the detection of methicillin-resistant Staphylococcus aureus and methicillin-sensitive S. aureus, and the company claims that it is the only marketed PCR-based test able to accurately discriminate between the pathogen strains.

MDI said that the test is currently available in the UK, Germany, Ireland, Switzerland, Spain, Austria, Australia, the Netherlands, Belgium, and Luxembourg.

Last week, MDI said that it received a notice of allowance from the US Patent and Trademark Office for a patent covering a key aspect of Detect-Ready MRSA (PCR Insider, 7/14/2011).

The Scan

WHO Seeks Booster Pause

According to CNN, the World Health Organization is calling for a moratorium on administering SARS-CoV-2 vaccine boosters until more of the world has received initial doses.

For Those Long Legs

With its genome sequence and subsequent RNAi analyses, researchers have examined the genes that give long legs to daddy longlegs, New Scientist says.

September Plans

The New York Times reports that the US Food and Drug Administration is aiming for early September for full approval of the Pfizer-BioNTech SARS-CoV-2 vaccine.

Nucleic Acids Research Papers on Targeting DNA Damage Response, TSMiner, VarSAn

In Nucleic Acids Research this week: genetic changes affecting DNA damage response inhibitor response, "time-series miner" approach, and more.